Last $74.93 USD
Change Today +1.31 / 1.78%
Volume 148.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 9:29 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$74.93
Previous Close
$73.62
Day High
$74.93
Day Low
$74.93
52 Week High
05/1/14 - $81.70
52 Week Low
11/26/13 - $55.93
Market Cap
94.6B
Average Volume 10 Days
441.3
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
--
Dividend
$3.11
Dividend Yield
4.15%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZNCF) Key Developments

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

AstraZeneca announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AstraZeneca's maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca's overall pipeline. AstraZeneca's Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility, with hundreds of thousands of square feet of administrative, production, warehouse, laboratory and utility space. The expansion project, which is anticipated to begin in December and expected to be complete in mid-2017, will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space. The expansion is also expected to bring a total of 300 new jobs to the site.

Astrazeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients

AstraZeneca presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. The two replicate Phase III studies, CLEAR1 and CLEAR2, evaluated lesinurad (200mg or 400mg oral) in combination with allopurinol in symptomatic gout patients not achieving target sUA levels on their current allopurinol dose. In both trials, lesinurad 200mg and 400mg, in combination with allopurinol, met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6 compared to allopurinol alone (CLEAR1 -- 28%, 54% and 59%; CLEAR2 -- 23%, 55% and 67% for allopurinol alone, lesinurad 200mg + allopurinol and lesinurad 400mg + allopurinol respectively). Among the key secondary endpoints of mean gout flare rates and patients with complete tophus resolution, no significant differences were observed for mean gout flare rates (end of Month 6 to 12) or patients with complete tophus resolution. The three most commonly reported adverse events across the CLEAR1 and CLEAR2 trials for patients receiving lesinurad in combination with allopurinol were upper respiratory tract infection, nasopharyngitis and back pain. The incidence of renal-related adverse events (including serious events) and incidence of kidney stones with lesinurad 200mg plus allopurinol was comparable to placebo plus allopurinol. The incidence of renal-related adverse events and kidney stones was higher with lesinurad 400mg plus allopurinol. Serum creatinine increases were observed, which resolved in most cases without interrupting study medication.

AstraZeneca PLC, Pharmacyclics, Inc. and Janssen Research & Development LLC Enter a Clinical Trial Collaboration

AstraZeneca, Pharmacyclics Inc. and Janssen Research & Development LLC have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech Inc. The study will assess the combination as a treatment for patients with hematologic cancers including Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, which are investigational uses for both compounds. MEDI4736 blocks the signals that help tumors avoid detection by the immune system, countering the tumor's immune-evading tactics. Ibrutinib blocks signals that tell malignant B cells (white blood cells that produce antibodies) to multiply and spread uncontrollably. Preclinical evidence suggests that the combination of these two agents may lead to an enhanced anti-tumor immune response. The phase I part of the trial is expected to establish a recommended dose regimen for the combination of MEDI4736 and ibrutinib, and the phase II part of the study will assess the safety and efficacy of the investigational combination. Under the terms of the agreement, the trial will be conducted by Pharmacyclics. The financial terms of the agreement have not been disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $74.93 USD +1.31

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.36 USD +2.17
Bristol-Myers Squibb Co $58.80 USD +0.19
Celgene Corp $108.20 USD +0.85
Eli Lilly & Co $67.36 USD +0.56
Novo Nordisk A/S kr265.80 DKK +2.00
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 91.0x
Price/Sales 3.6x
Price/Book 4.6x
Price/Cash Flow 91.0x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.